PTC Therapeutics Net Income
| PTCT Stock | USD 69.45 1.25 1.77% |
As of the 13th of February 2026, PTC Therapeutics owns the coefficient of variation of (202,796), and Market Risk Adjusted Performance of (0). In relation to fundamental indicators, the technical analysis model allows you to check practical technical drivers of PTC Therapeutics, as well as the relationship between them.
PTC Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.4823 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -503.1 M | -478 M | |
| Net Loss | -327 M | -343.3 M | |
| Net Loss | -327 M | -343.3 M | |
| Net Loss | (5.44) | (5.71) | |
| Net Income Per E B T | 1.15 | 1.10 |
PTC | Net Income | Build AI portfolio with PTC Stock |
The evolution of Net Income for PTC Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how PTC Therapeutics compares to historical norms and industry peers.
Latest PTC Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of PTC Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in PTC Therapeutics financial statement analysis. It represents the amount of money remaining after all of PTC Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is PTC Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PTC Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (363.3 M) | 10 Years Trend |
|
Net Income |
| Timeline |
PTC Net Income Regression Statistics
| Arithmetic Mean | (238,954,290) | |
| Coefficient Of Variation | (87.96) | |
| Mean Deviation | 178,964,466 | |
| Median | (170,447,000) | |
| Standard Deviation | 210,191,735 | |
| Sample Variance | 44180.6T | |
| Range | 657.5M | |
| R-Value | (0.83) | |
| Mean Square Error | 14721.5T | |
| R-Squared | 0.69 | |
| Significance | 0.000039 | |
| Slope | (34,515,789) | |
| Total Sum of Squares | 706889T |
PTC Net Income History
Other Fundumenentals of PTC Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
PTC Therapeutics Net Income component correlations
PTC Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for PTC Therapeutics is extremely important. It helps to project a fair market value of PTC Stock properly, considering its historical fundamentals such as Net Income. Since PTC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PTC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PTC Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will PTC introduce new products? Factors like these will boost the valuation of PTC Therapeutics. Anticipated expansion of PTC directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 8.58 | Revenue Per Share | Quarterly Revenue Growth 0.072 | Return On Assets | Return On Equity |
Understanding PTC Therapeutics requires distinguishing between market price and book value, where the latter reflects PTC's accounting equity. The concept of intrinsic value - what PTC Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push PTC Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between PTC Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PTC Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, PTC Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
PTC Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to PTC Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of PTC Therapeutics.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in PTC Therapeutics on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding PTC Therapeutics or generate 0.0% return on investment in PTC Therapeutics over 90 days. PTC Therapeutics is related to or competes with Alkermes Plc, Krystal Biotech, Arrowhead Pharmaceuticals, TG Therapeutics, Vaxcyte, Arcellx, and Avidity Biosciences. PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of med... More
PTC Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure PTC Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess PTC Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 11.9 | |||
| Value At Risk | (3.49) | |||
| Potential Upside | 3.41 |
PTC Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for PTC Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as PTC Therapeutics' standard deviation. In reality, there are many statistical measures that can use PTC Therapeutics historical prices to predict the future PTC Therapeutics' volatility.| Risk Adjusted Performance | 0.0057 | |||
| Jensen Alpha | (0.08) | |||
| Total Risk Alpha | (0.19) | |||
| Treynor Ratio | (0.01) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PTC Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
PTC Therapeutics February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0057 | |||
| Market Risk Adjusted Performance | (0) | |||
| Mean Deviation | 1.5 | |||
| Coefficient Of Variation | (202,796) | |||
| Standard Deviation | 2.1 | |||
| Variance | 4.41 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.08) | |||
| Total Risk Alpha | (0.19) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 11.9 | |||
| Value At Risk | (3.49) | |||
| Potential Upside | 3.41 | |||
| Skewness | (0.60) | |||
| Kurtosis | 2.64 |
PTC Therapeutics Backtested Returns
PTC Therapeutics retains Efficiency (Sharpe Ratio) of -0.0534, which implies the firm had a -0.0534 % return per unit of risk over the last 3 months. PTC Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check PTC Therapeutics' market risk adjusted performance of (0), and Coefficient Of Variation of (202,796) to confirm the risk estimate we provide. The company owns a Beta (Systematic Risk) of 0.98, which implies possible diversification benefits within a given portfolio. PTC Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, PTC Therapeutics is expected to follow. At this point, PTC Therapeutics has a negative expected return of -0.12%. Please make sure to check PTC Therapeutics' total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if PTC Therapeutics performance from the past will be repeated at future time.
Auto-correlation | 0.27 |
Poor predictability
PTC Therapeutics has poor predictability. Overlapping area represents the amount of predictability between PTC Therapeutics time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of PTC Therapeutics price movement. The serial correlation of 0.27 indicates that nearly 27.0% of current PTC Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.27 | |
| Spearman Rank Test | -0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 2.86 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
PTC Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, PTC Therapeutics reported net income of (363.3 Million). This is 206.45% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 163.63% higher than that of the company.
PTC Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PTC Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PTC Therapeutics could also be used in its relative valuation, which is a method of valuing PTC Therapeutics by comparing valuation metrics of similar companies.PTC Therapeutics is currently under evaluation in net income category among its peers.
PTC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of PTC Therapeutics from analyzing PTC Therapeutics' financial statements. These drivers represent accounts that assess PTC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PTC Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 2.8B | 2.7B | 2.1B | 3.5B | 3.1B | 3.3B | |
| Enterprise Value | 3.9B | 3.9B | 3.7B | 5.2B | 4.6B | 4.9B |
PTC Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, PTC Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to PTC Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
PTC Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in PTC Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of PTC Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing PTC Therapeutics' value.| Shares | Bank Of America Corp | 2025-06-30 | 1.4 M | Franklin Resources Inc | 2025-06-30 | 1.3 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.2 M | Tang Capital Management Llc | 2025-06-30 | 1.1 M | Driehaus Capital Management Llc | 2025-06-30 | 1.1 M | Pictet Asset Manangement Sa | 2025-06-30 | 1 M | Nuveen, Llc | 2025-06-30 | 968.9 K | Renaissance Technologies Corp | 2025-06-30 | 963.3 K | Rockefeller Capital Management L.p. | 2025-06-30 | 926.2 K | Vanguard Group Inc | 2025-06-30 | 8.8 M | Rtw Investments, Llc | 2025-06-30 | 7.7 M |
PTC Fundamentals
| Return On Equity | -77.4 | ||||
| Return On Asset | 0.26 | ||||
| Profit Margin | 0.42 % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 4.42 B | ||||
| Shares Outstanding | 80.29 M | ||||
| Shares Owned By Insiders | 2.59 % | ||||
| Shares Owned By Institutions | 97.41 % | ||||
| Number Of Shares Shorted | 10.08 M | ||||
| Price To Earning | (5.67) X | ||||
| Price To Book | 1,743 X | ||||
| Price To Sales | 3.19 X | ||||
| Revenue | 806.78 M | ||||
| Gross Profit | 1.28 B | ||||
| EBITDA | (120.46 M) | ||||
| Net Income | (363.3 M) | ||||
| Cash And Equivalents | 288.43 M | ||||
| Cash Per Share | 4.01 X | ||||
| Total Debt | 2.47 B | ||||
| Current Ratio | 1.23 X | ||||
| Book Value Per Share | (1.95) X | ||||
| Cash Flow From Operations | (107.69 M) | ||||
| Short Ratio | 7.58 X | ||||
| Earnings Per Share | 8.58 X | ||||
| Price To Earnings To Growth | 0.81 X | ||||
| Target Price | 88.5 | ||||
| Number Of Employees | 939 | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 5.68 B | ||||
| Total Asset | 1.71 B | ||||
| Retained Earnings | (3.65 B) | ||||
| Working Capital | 784.55 M | ||||
| Current Asset | 355.95 M | ||||
| Current Liabilities | 45.39 M | ||||
| Net Asset | 1.71 B |
About PTC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.